| 000 | 01774 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513155138.0 | ||
| 264 | 0 | _c19990223 | |
| 008 | 199902s 0 0 eng d | ||
| 022 | _a1078-0432 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGore, S D | |
| 245 | 0 | 0 |
_aA phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. _h[electronic resource] |
| 260 |
_bClinical cancer research : an official journal of the American Association for Cancer Research _cNov 1998 |
||
| 300 |
_a2677-89 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 |
_aBone Marrow _xdrug effects |
| 650 | 0 | 4 |
_aDNA Topoisomerases, Type I _xmetabolism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukocyte Count _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPrecursor Cell Lymphoblastic Leukemia-Lymphoma _xdrug therapy |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins c-bcl-2 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aTopoisomerase I Inhibitors |
| 650 | 0 | 4 |
_aTopotecan _xadverse effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aRowinsky, E K | |
| 700 | 1 | _aMiller, C B | |
| 700 | 1 | _aGriffin, C | |
| 700 | 1 | _aChen, T L | |
| 700 | 1 | _aBorowitz, M | |
| 700 | 1 | _aDonehower, R C | |
| 700 | 1 | _aBurks, K L | |
| 700 | 1 | _aArmstrong, D K | |
| 700 | 1 | _aBurke, P J | |
| 700 | 1 | _aGrever, M R | |
| 700 | 1 | _aKaufmann, S H | |
| 773 | 0 |
_tClinical cancer research : an official journal of the American Association for Cancer Research _gvol. 4 _gno. 11 _gp. 2677-89 |
|
| 999 |
_c9793846 _d9793846 |
||